Details of the Drug
General Information of Drug (ID: DMCHV4I)
Drug Name |
Rifapentine
|
||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
RIFAPENTINE; Rifapentina; Rifapentinum; Cyclopentylrifampicin; Rifamycin AF/ACPP; Antibiotic DL 473IT; KTC 1; 61379-65-5; MDL 473; DRG-0283; DL 473; R-773; R 77-3; 3-(N-(4-Cyclopentyl-1-piperazinyl)formimidoyl)rifamycin; 3-(4-Cyclopentyl-1-piperazinyl)iminomethylrifamycin SV; 3-(((4-Cyclopentyl-1-piperazinyl)imino)methyl)rifamycin; Rifapentin,(S); NCGC00167431-01; ZINC169621228; NCGC00167431-03; AN-15578; RPE
|
||||||||||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||||||||||
Therapeutic Class |
Antituberculosis Agents
|
||||||||||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||||||||||
Structure | |||||||||||||||||||||||||||||||
3D MOL is unavailable | 2D MOL | ||||||||||||||||||||||||||||||
#Ro5 Violations (Lipinski): 4 | Molecular Weight (mw) | 877 | |||||||||||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 6.7 | ||||||||||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 6 | ||||||||||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 6 | ||||||||||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 15 | ||||||||||||||||||||||||||||||
ADMET Property |
|
||||||||||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||||||||||
Combinatorial Drugs (CBD) | Click to Jump to the Detailed CBD Information of This Drug | ||||||||||||||||||||||||||||||
Repurposed Drugs (RPD) | Click to Jump to the Detailed RPD Information of This Drug | ||||||||||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Drug-Metabolizing Enzyme (DME) |
|
||||||||||||||||||||||||||||||||||||
Drug Off-Target (DOT) |
|
||||||||||||||||||||||||||||||||||||
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||||||||||||
Drug-Drug Interaction (DDI) Information of This Drug
Coadministration of a Drug Treating the Same Disease as Rifapentine
Coadministration of a Drug Treating the Disease Different from Rifapentine (Comorbidity)
|
Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug
References
1 | Rifapentine FDA Label | ||||
---|---|---|---|---|---|
2 | Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8. | ||||
3 | The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. | ||||
4 | Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches | ||||
5 | Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1998 Jul;42(7):1853-7. | ||||
6 | Inhibitory potential of twenty five anti-tuberculosis drugs on CYP activities in human liver microsomes. Biol Pharm Bull. 2015;38(9):1425-9. | ||||
7 | Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. Biochem Pharmacol. 2011 Dec 1;82(11):1747-56. | ||||
8 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41. | ||||
9 | Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug Metab Dispos. 2006 Oct;34(10):1742-8. | ||||
10 | Product Information. Pretomanid (pretomanid). The Global Alliance for TB Drug Development, New York, NY. | ||||
11 | Cerner Multum, Inc. "UK Summary of Product Characteristics.". | ||||
12 | Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA. | ||||
13 | Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261] | ||||
14 | Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL. | ||||
15 | Canadian Pharmacists Association. | ||||
16 | Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI. | ||||
17 | Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ. | ||||
18 | Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO. | ||||
19 | Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ. | ||||
20 | Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA. | ||||
21 | Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ. | ||||
22 | Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ. | ||||
23 | Cerner Multum, Inc. "Australian Product Information.". | ||||
24 | Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN. | ||||
25 | Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674] | ||||
26 | Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA. | ||||
27 | Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
28 | Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ. | ||||
29 | Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY. | ||||
30 | Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899] | ||||
31 | Product Information. Hectorol (doxercalciferol). Genzyme Corporation, Cambridge, MA. | ||||
32 | Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY. | ||||
33 | Caraco Y, Sheller J, Wood AJ "Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects." J Pharmacol Exp Ther 281 (1997): 330-6. [PMID: 9103514] | ||||
34 | Product Information. Stivarga (regorafenib). Bayer Pharmaceutical Inc, West Haven, CT. | ||||
35 | Archer JS, Archer DF "Oral contraceptive efficacy and antibiotic interaction: A myth debunked." J Am Acad Dermatol 46 (2002): 917-23. [PMID: 12063491] | ||||
36 | Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT. | ||||
37 | Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL. | ||||
38 | Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD. | ||||
39 | Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137] | ||||
40 | Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ. | ||||
41 | Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA. | ||||
42 | Back DJ, Breckenridge AM, Crawford F, et al. "The effect of rifampicin on norethisterone pharmacokinetics." Eur J Clin Pharmacol 15 (1979): 193-7. [PMID: 37091] | ||||
43 | Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT. | ||||
44 | Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA. | ||||
45 | Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC. | ||||
46 | Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL. | ||||
47 | Product Information. Qinlock (ripretinib). Deciphera Pharmaceuticals, Waltham, MA. | ||||
48 | Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA. | ||||
49 | Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ. | ||||
50 | Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ. | ||||
51 | Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12. [PMID: 10391416] | ||||
52 | Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC. | ||||
53 | Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC. | ||||
54 | Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ. | ||||
55 | Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ. | ||||
56 | Cerner Multum, Inc. "Canadian Product Information.". | ||||
57 | Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE. | ||||
58 | Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA. | ||||
59 | Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ. | ||||
60 | Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD. | ||||
61 | Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY. | ||||
62 | Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA. | ||||
63 | Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
64 | Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA. | ||||
65 | Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY. | ||||
66 | Product Information. Gilotrif (afatinib). Boehringer Ingelheim, Ridgefield, CT. | ||||
67 | Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA. | ||||
68 | Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
69 | Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA. | ||||
70 | Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL. | ||||
71 | Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA. | ||||
72 | Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE. | ||||
73 | Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE. | ||||
74 | Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO. | ||||
75 | Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA. | ||||
76 | Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT. | ||||
77 | Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC. | ||||
78 | Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
79 | Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA. | ||||
80 | Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
81 | Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE. | ||||
82 | Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA. | ||||
83 | Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071] | ||||
84 | Product Information. Symproic (naldemedine). Shionogi USA Inc, Florham Park, NJ. | ||||
85 | EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.". | ||||
86 | Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ. | ||||
87 | Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ. | ||||
88 | Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC. | ||||
89 | Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA. | ||||
90 | Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA. | ||||
91 | Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA. | ||||
92 | Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL. | ||||
93 | Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA. | ||||
94 | Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ. | ||||
95 | Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ. | ||||
96 | Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT. | ||||
97 | Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168] | ||||
98 | Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL. | ||||
99 | Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ. | ||||
100 | Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA. | ||||
101 | Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA. | ||||
102 | Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
103 | Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990] | ||||
104 | Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA. | ||||
105 | Product Information. Kisqali (ribociclib). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
106 | Martin P, Oliver S, Robertson J, Kennedy SJ, Read J, Duvauchelle T "Pharmacokinetic drug interactions with vandetanib during cadministration with rifampicin or itraconazole." Drugs R D 11 (2011): 37-51. [PMID: 21410294] | ||||
107 | Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993. | ||||
108 | Product Information. Pomalyst (pomalidomide). QLT Phototherapeutics Inc, Vancouver, AZ. | ||||
109 | Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA. | ||||
110 | Nomo, Zamora, Schuck, et al. "Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting." PubMed 84 (2018): 1. [PMID: 29341245] | ||||
111 | Product Information. Brilinta (ticagrelor). Astra-Zeneca Pharmaceuticals, Wilmington, DE. | ||||
112 | Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA. | ||||
113 | Product Information. Onglyza (saxagliptin). Bristol-Myers Squibb, Princeton, NJ. | ||||
114 | Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT. | ||||
115 | Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL. | ||||
116 | Gelosa P, Castiglioni L, Tenconi M, et.al "Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)" Pharmacol Res 135 (2018): 60-79. [PMID: 30040996] | ||||